1
|
Ma X, Rawnsley DR, Kovacs A, Islam M, Murphy JT, Zhao C, Kumari M, Foroughi L, Liu H, Qi K, Diwan A, Hyrc K, Evans S, Satoh T, French BA, Margulies KB, Javaheri A, Razani B, Mann DL, Mani K, Diwan A. TRAF2, an Innate Immune Sensor, Reciprocally Regulates Mitophagy and Inflammation to Maintain Cardiac Myocyte Homeostasis. JACC Basic Transl Sci 2022; 7:223-243. [PMID: 35411325 PMCID: PMC8993766 DOI: 10.1016/j.jacbts.2021.12.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Revised: 12/01/2021] [Accepted: 12/02/2021] [Indexed: 12/26/2022]
Abstract
Mitochondria are essential for cardiac myocyte function, but damaged mitochondria trigger cardiac myocyte death. Although mitophagy, a lysosomal degradative pathway to remove damaged mitochondria, is robustly active in cardiac myocytes in the unstressed heart, its mechanisms and physiological role remain poorly defined. We discovered a critical role for TRAF2, an innate immunity effector protein with E3 ubiquitin ligase activity, in facilitating physiological cardiac myocyte mitophagy in the adult heart, to prevent inflammation and cell death, and maintain myocardial homeostasis.
Collapse
Key Words
- AAV9, adeno-associated virus serotype 9
- ER, endoplasmic reticulum
- FS, fractional shortening
- GFP, green fluorescent protein
- IP, intraperitoneal
- LV, left ventricular
- MAM, mitochondria-associated membranes
- MCM, MerCreMer
- MEF, murine embryonic fibroblast
- PINK1, PTEN-induced kinase 1
- RFP, red fluorescent protein
- TLR9, toll-like receptor 9
- TRAF2
- TRAF2, tumor necrosis factor receptor-associated factor-2
- TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling
- cTnT, cardiac troponin T
- cell death
- inflammation
- mitophagy
Collapse
Affiliation(s)
- Xiucui Ma
- Center for Cardiovascular Research and Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
- John Cochran VA Medical Center, St. Louis, Missouri, USA
| | - David R. Rawnsley
- Center for Cardiovascular Research and Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Attila Kovacs
- Center for Cardiovascular Research and Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Moydul Islam
- Center for Cardiovascular Research and Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
| | - John T. Murphy
- Center for Cardiovascular Research and Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
- John Cochran VA Medical Center, St. Louis, Missouri, USA
| | - Chen Zhao
- Center for Cardiovascular Research and Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Minu Kumari
- Center for Cardiovascular Research and Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Layla Foroughi
- Center for Cardiovascular Research and Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
- John Cochran VA Medical Center, St. Louis, Missouri, USA
| | - Haiyan Liu
- Center for Cardiovascular Research and Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
- John Cochran VA Medical Center, St. Louis, Missouri, USA
| | - Kevin Qi
- Center for Cardiovascular Research and Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Aaradhya Diwan
- Center for Cardiovascular Research and Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Krzysztof Hyrc
- Alafi Neuroimaging Laboratory, Washington University School of Medicine, St. Louis, Missouri, USA
- Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Sarah Evans
- Center for Cardiovascular Research and Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Takashi Satoh
- Department of Immune Regulation, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| | - Brent A. French
- Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA
| | - Kenneth B. Margulies
- Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Ali Javaheri
- Center for Cardiovascular Research and Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Babak Razani
- Center for Cardiovascular Research and Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
- John Cochran VA Medical Center, St. Louis, Missouri, USA
| | - Douglas L. Mann
- Center for Cardiovascular Research and Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
- John Cochran VA Medical Center, St. Louis, Missouri, USA
- Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Kartik Mani
- Center for Cardiovascular Research and Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
- John Cochran VA Medical Center, St. Louis, Missouri, USA
| | - Abhinav Diwan
- Center for Cardiovascular Research and Cardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
- John Cochran VA Medical Center, St. Louis, Missouri, USA
- Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri, USA
- Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA
- Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri, USA
| |
Collapse
|
2
|
Maruelli S, Besio R, Rousseau J, Garibaldi N, Amiaud J, Brulin B, Layrolle P, Escriou V, Rossi A, Trichet V, Forlino A. Osteoblasts mineralization and collagen matrix are conserved upon specific Col1a2 silencing. Matrix Biol Plus 2020; 6-7:100028. [PMID: 33543025 PMCID: PMC7852305 DOI: 10.1016/j.mbplus.2020.100028] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2019] [Revised: 01/24/2020] [Accepted: 01/24/2020] [Indexed: 11/10/2022] Open
Abstract
Classical osteogenesis imperfecta (OI) is an inherited rare brittle bone disease caused by dominant mutations in the COL1A1 or COL1A2 genes, encoding for the α chains of collagen type I. The definitive cure for the disease will require a gene therapy approach, aimed to correct or suppress the mutant allele. Interestingly, individuals lacking α2(I) chain and synthetizing collagen α1(I)3 homotrimers do not show bone phenotype, making appealing a bone specific COL1A2 silencing approach for OI therapy. To this aim, three different Col1a2-silencing RNAs (siRNAs), −3554, −3825 and −4125, selected at the 3′-end of the murine Col1a2 transcript were tested in vitro and in vivo. In murine embryonic fibroblasts Col1a2-siRNA-3554 was able to efficiently and specifically target the Col1a2 mRNA and to strongly reduce α2(I) chain expression. Its efficiency and specificity were also demonstrated in primary murine osteoblasts, whose mineralization was preserved. The efficiency of Col1a2-siRNA-3554 was proved also in vivo. Biphasic calcium phosphate implants loaded with murine mesenchymal stem cells were intramuscularly transplanted in nude mice and injected with Col1a2-siRNA-3554 three times a week for three weeks. Collagen α2 silencing was demonstrated both at mRNA and protein level and Masson's Trichrome staining confirmed the presence of newly formed collagen matrix. Our data pave the way for further investigation of Col1a2 silencing and siRNA delivery to the bone tissue as a possible strategy for OI therapy. Identification of a specific and efficient Col1a2 siRNA Silencing of Col1a2 allows osteoblasts mineralization. Col1a2 silencing is not impairing matrix deposition in vivo.
Collapse
Key Words
- BCP, biphasic calcium phosphate
- Collagen
- D-MEM, Dulbecco-modified Eagle's medium
- EDS, Ehlers Danlos syndrome
- EGFP, enhanced green fluorescent protein
- FBS, fetal bovine serum
- Gene therapy
- MEF, murine embryonic fibroblast
- MSC, mesenchymal stem cell
- NMD, nonsense mediated RNA decay
- OI, osteogenesis imperfecta
- Osteogenesis imperfecta
- PBS, phosphate buffered saline
- RNAi, RNA interference
- SDS, sodium dodecyl sulphate
- Silencing
- TRAP, tartrate-resistant acid phosphatase
- shRNA, short hairpin RNA
- siRNA
- siRNA, small interfering RNA
Collapse
Affiliation(s)
- Silvia Maruelli
- Department of Molecular Medicine, Biochemistry Unit, University of Pavia, Pavia, Italy
| | - Roberta Besio
- Department of Molecular Medicine, Biochemistry Unit, University of Pavia, Pavia, Italy
| | - Julie Rousseau
- INSERM, Université de Nantes, UMR1238, Phy-Os, Bone sarcomas and remodeling of calcified tissues, Faculty of Medicine, University of Nantes, Nantes, France
| | - Nadia Garibaldi
- Department of Molecular Medicine, Biochemistry Unit, University of Pavia, Pavia, Italy
| | - Jérôme Amiaud
- INSERM, Université de Nantes, UMR1238, Phy-Os, Bone sarcomas and remodeling of calcified tissues, Faculty of Medicine, University of Nantes, Nantes, France
| | - Bénédicte Brulin
- INSERM, Université de Nantes, UMR1238, Phy-Os, Bone sarcomas and remodeling of calcified tissues, Faculty of Medicine, University of Nantes, Nantes, France
| | - Pierre Layrolle
- INSERM, Université de Nantes, UMR1238, Phy-Os, Bone sarcomas and remodeling of calcified tissues, Faculty of Medicine, University of Nantes, Nantes, France
| | | | - Antonio Rossi
- Department of Molecular Medicine, Biochemistry Unit, University of Pavia, Pavia, Italy
| | - Valerie Trichet
- INSERM, Université de Nantes, UMR1238, Phy-Os, Bone sarcomas and remodeling of calcified tissues, Faculty of Medicine, University of Nantes, Nantes, France
| | - Antonella Forlino
- Department of Molecular Medicine, Biochemistry Unit, University of Pavia, Pavia, Italy
| |
Collapse
|
3
|
Comet NR, Aguiló JI, Rathoré MG, Catalán E, Garaude J, Uzé G, Naval J, Pardo J, Villalba M, Anel A. IFNα signaling through PKC-θ is essential for antitumor NK cell function. Oncoimmunology 2014; 3:e948705. [PMID: 25960930 DOI: 10.4161/21624011.2014.948705] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2014] [Accepted: 06/06/2014] [Indexed: 11/19/2022] Open
Abstract
We have previously shown that the development of a major histocompatibility complex class I (MHC-I)-deficient tumor was favored in protein kinase C-θ knockout (PKC-θ-/-) mice compared to that occurring in wild-type mice. This phenomenon was associated with scarce recruitment of natural killer (NK) cells to the tumor site, as well as impaired NK cell activation and reduced cytotoxicity ex vivo. Poly-inosinic:cytidylic acid (poly I:C) treatment activated PKC-θ in NK cells depending on the presence of a soluble factor produced by a different splenocyte subset. In the present work, we sought to analyze whether interleukin-15 (IL-15) and/or interferon-α (IFNα) mediate PKC-θ-dependent antitumor NK cell function. We found that IL-15 improves NK cell viability, granzyme B expression, degranulation capacity and interferon-γ (IFNγ) secretion independently of PKC-θ. In contrast, we found that IFNα improves the degranulation capability of NK cells against target cancer cells in a PKC-θ-dependent fashion both ex vivo and in vivo. Furthermore, IFNα induces PKC-θ auto-phosphorylation in NK cells, in a signal transduction pathway involving both phosphatidylinositol-3-kinase (PI3K) and phospholipase-C (PLC) activation. PKC-θ dependence was further implicated in IFNα-induced transcriptional upregulation of chemokine (C-X-C motif) ligand 10 (CXCL10), a signal transducer and activator of transcription-1 (STAT-1)-dependent target of IFNα. The absence of PKC-θ did not affect IFNα-induced STAT-1 Tyr701 phosphorylation but affected the increase in STAT-1 phosphorylation on Ser727, attenuating CXCL10 secretion. This connection between IFNα and PKC-θ in NK cells may be exploited in NK cell-based tumor immunotherapy.
Collapse
Key Words
- CDK8, cyclin-dependent kinase 8
- CXCL10
- CXCL10, (C-X-C motif) ligand 10/CXCL10
- FCS, fetal calf serum
- IFN-α, IL-15
- IFNA1
- IFNα, interferon-α
- IFNγ, interferon-γ, IFNG
- IL-15, interleukin-15/IL15
- MACS, magnetic cell separation
- MEF, murine embryonic fibroblast
- MHC-I, major histocompability complex class I/MHC-I
- NK cells
- NK, natural killer
- PI3K, phosphatidylinositol-3-kinase
- PKC-θ
- PKC-θ, protein kinase C-θ, PRKCQ
- PLC, phospholipase-C
- Poly I:C, poly-inosinic:cytidilic acid
- RT-PCR, real-time polymerase chain reaction
- STAT-1, signal transducer and activator of transcription-1/STAT1.
- mAb, monoclonal antibody
Collapse
Affiliation(s)
- Natalia R Comet
- Apoptosis, Immunity & Cancer Group; Department of Biochemistry and Molecular and Cell Biology ; University of Zaragoza and Aragón Health Research Institute (IIS Aragón) ; Zaragoza, Spain
| | - Juan Ignacio Aguiló
- Apoptosis, Immunity & Cancer Group; Department of Biochemistry and Molecular and Cell Biology ; University of Zaragoza and Aragón Health Research Institute (IIS Aragón) ; Zaragoza, Spain
| | - Moeez G Rathoré
- INSERM U1040; Université de Montpellier 1; UFR Médecine ; Montpellier, France
| | - Elena Catalán
- Apoptosis, Immunity & Cancer Group; Department of Biochemistry and Molecular and Cell Biology ; University of Zaragoza and Aragón Health Research Institute (IIS Aragón) ; Zaragoza, Spain
| | - Johan Garaude
- INSERM U1040; Université de Montpellier 1; UFR Médecine ; Montpellier, France
| | - Gilles Uzé
- CNRS UMR 5235; Université de Montpellier II; Place Eugene Bataillon ; Montpellier, France
| | - Javier Naval
- Apoptosis, Immunity & Cancer Group; Department of Biochemistry and Molecular and Cell Biology ; University of Zaragoza and Aragón Health Research Institute (IIS Aragón) ; Zaragoza, Spain
| | - Julián Pardo
- Immune Effector Cells Group; IIS Aragón; Biomedical Research Center of Aragón (CIBA); Nanoscience Institute of Aragon (INA); Zaragoza, Spain ; Aragón I+D Foundation (ARAID) ; Zaragoza, Spain
| | - Martín Villalba
- INSERM U1040; Université de Montpellier 1; UFR Médecine ; Montpellier, France ; Institut de Recherche en Biothérapie (IRB); CHU Montpellier ; Montpellier, France
| | - Alberto Anel
- Apoptosis, Immunity & Cancer Group; Department of Biochemistry and Molecular and Cell Biology ; University of Zaragoza and Aragón Health Research Institute (IIS Aragón) ; Zaragoza, Spain
| |
Collapse
|